Overview

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2024-12-26

Target enrollment:

Participant gender:

Summary

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Treatments:

Antibodies
Antibodies, Monoclonal
Bevacizumab
Cetuximab
Erlotinib Hydrochloride
Nivolumab
Osimertinib